Crossmark

High-dose denosumab (Xgeva®) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients

Crossref DOI link: https://doi.org/10.1007/s00520-024-08974-6

Published Online: 2024-11-05

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Moon, Chiho

Kim, Hyounmin

Park, Jin Hoo

Park, Wonse

Kim, Hyung Jun

Jung, Young-Soo

Kim, Jun-Young https://orcid.org/0000-0002-6596-6135
License Information

Text and Data Mining valid from 2024-11-05

Version of Record valid from 2024-11-05
More Information

Article History

Received: 16 February 2024

Accepted: 29 October 2024

First Online: 5 November 2024

Declarations

:

: This study received approval from the Institutional Research Ethics Committee of Yonsei University College of Dentistry (IRB No.2–2023-0072). Considering the retrospective nature of this study, the IRB waived the requirement for individual informed consent.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below